Eli Lilly and Company (LLY) Stock Forecast
LLY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.39 / 5 from 31 analysts
- Price target
- $1,328.05 average of analyst targets
- Upside to target
- +5.7% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $5.38
- 52-week range
- $799.57 – $1,280.34
LLY analyst ratings
31 analystsNumber of analysts at each rating.
LLY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LLY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.11 | $4.65 | $10.68 | $7.02 | +1.2% | 18 |
| Current fiscal year (2026) | $35.02 | $31.33 | $38.56 | $24.21 | +44.6% | 28 |
| Next fiscal year (2027) | $47.19 | $40.73 | $52.34 | $35.02 | +34.8% | 26 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LLY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $22.50B | $21.52B | $23.81B | +27.8% | 17 |
| Current fiscal year (2026) | $88.50B | $83.43B | $91.62B | +35.8% | 29 |
| Next fiscal year (2027) | $102.01B | $92.60B | $109.41B | +15.3% | 27 |
LLY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LLY revenue: reported and forecast
LLY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.44 | $9.87 | $9.87 | $8.09 | $7.11 | −24.7% | 3 up · 7 down |
| Current fiscal year (2026) | $34.85 | $36.73 | $36.73 | $35.77 | $35.02 | +0.5% | 5 up · 8 down |
| Next fiscal year (2027) | $44.91 | $47.33 | $47.32 | $47.64 | $47.19 | +5.1% | 7 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LLY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LLY beat in 10 of 12.
What analysts expect from LLY
31 analysts cover Eli Lilly; their consensus rating is buy (4.39 on a 1–5 scale, where 5 is a strong buy). The average price target is $1,328.05, 5.7% above the latest close of $1,257.03. Analysts expect earnings of $35.02 per share for 2026, +44.6% from a year earlier. For 2027 the average estimate is $47.19 per share on revenue of $102.0 billion. Eli Lilly beat the EPS estimate in 10 of the last 12 quarters.
Related: LLY income statement, LLY key metrics, LLY chart. See the LLY stock overview for the latest quote and news.
LLY forecast FAQ
What is Eli Lilly's price target?
The average analyst price target for Eli Lilly is $1,328.05, 5.7% above the latest close of $1,257.03.
Is Eli Lilly a buy, hold or sell?
Of 31 analysts covering Eli Lilly, 20 rate it a strong buy, 6 a buy, 3 a hold, 1 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eli Lilly's EPS forecast?
Analysts forecast $35.02 per share for 2026 (range $31.33 to $38.56); for 2027 the estimate is $47.19.
What is Eli Lilly's revenue forecast?
The average revenue estimate for 2026 is $88.5 billion, growth of 35.8%; for 2027 it is $102.0 billion.
When does Eli Lilly report earnings?
Eli Lilly is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $5.38.
Does Eli Lilly usually beat earnings estimates?
Eli Lilly reported EPS at or above the analyst estimate in 10 of the last 12 quarters.